


Biocartis Idylla Microsatellite Instability Assay Shows High Concordance with PCR and IHC for Microsatellite Instability Status in Colorectal Cancer

Introduction

Determination of mismatch repair (MMR) and/or microsatellite instability (MSI) status in colorectal cancer (CRC) is recommended to aid in the identification of patients with Lynch syndrome or as a prognostic indicator. In addition, it is becoming increasingly important as predictive biomarker for cancer immunotherapy. Current molecular testing methods for MSI are often labor intensive and require comparison to normal tissue. In this retrospective study, we examine the fully automated Biocartis MSI Assay (research use only), capable of MSI determination without the need to analyze normal tissue.

Materials and Methods

50 archived formalin fixed, paraffin embedded (FFPE) CRC specimens with known MSI status were selected for analysis on the Biocartis Idylla system. Both MMR IHC (MLH1, MSH2, MSH6 and PMS2) and a lab-developed (LDT) PCR assay (BAT-25, BAT-26, NR-21, NR-24 and NR-27) were used as reference methods for determination of MSI status on all 50 samples. The Idylla MSI cartridge assesses microsatellite instability at 7 novel loci in the ACVR2A, BTBD7, DID01, MRE11, RYR3, SEC31A and SULF2 genes by PCR amplification followed by high-resolution melting curve analysis. For each sample, MSI-High (MSI-H) is called if 2 or more biomarkers demonstrate instability; microsatellite stable (MSS) call is made if o or 1 biomarkers are instable. For the two PCR MSI methods (Idylla and the PCR-based assay), analysis was performed from a single 10µm FFPE section. In both cases, a macrodissection was performed. For the LDT PCR method, DNA was extracted and then analyzed; for Idylla, FFPE was inserted directly into the MSI assay cartridge.




The Idylla MSI Test

Key Characteristics

- 1. MSI detection based on 7 novel biomarkers
- 2. Results available in 150 minutes
- 3. Less than 2 minutes of hands-on time 4. Directly on FFPE tissue sections
- 5. No need for normal tissue sample
- 6. PCR based assay





MSS = WT = A1

Alexander Craig Mackinnon, MD, PhD and Stephanie Springborn, MS Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin

Post-analytical

Clinical and is family fore for Annual States And the factory of the fact factor for the second states
 Non
 Non
 Non

 Non
 Non
 Non
 Non

 Non
 Non
 Non
 Non

 Non
 Non
 Non
 Non

Specimen Requirements

5 µm FFPE glass mounted tissue section 10 µm FFPE tissue section (CURLS) Neoplastic cell content (if < 20%, macro-dissection needed)

Idylla MSI Biomarkers

7 homopolymers frequently mutated in MSI-H cancers

ACVR2A SULF1 SEC31A BTBD7 MRE11 DIDO1 RYR3

These biomarkers are different from the Bethesda markers

Idylla™ MSI Result Report

The Idylla[™] MSI Assay will make an individual mutation call for each of the 7 biomarkers

- Mutation Detected
- No Mutation Detected

Invalid

The Idylla[™] MSI Assay will also make an overall MSI determination:

- MSI-H $\rightarrow \geq 2$ of the 7 markers are mutant
- MSS \rightarrow <2 of the 7 markers are mutant
- Invalid \rightarrow >2 of the 7 markers are invalid



Idylla MSI Validation Data

Design

• 50 CRC FFPE samples were analyzed by 3 methods: Idylla MSI, LDT MSI and MMR IHC

Results

- Results were available for 50 samples
- Concordance to LDT MSI: 100%
- PPV = 100% (40/40)
- NPV = 100% (10/10)
- Concordance to MMR IHC: 100%
- Overall Failure Rates:
- MCW Assays = 0% - Idylla = 0%

Summary of Idylla[™] MSI Test

>95% concordance of the 7 novel MSI biomarkers with \equiv commercial and LDT PCR tests and IHC

Fast and reliable information on MSI status

Unbiased result reporting

Significantly lower failure rate compared to standard of care molecular methods

No need for normal tissue samples


The MSI Test is currently in development. Product characteristics mentioned are anticipated but not yet validated. (1) De Craene B. et al. Idylla MSI in gastric samples. ESMO 2017 poster 697P (2) Maertens G. et al. Idylla MSI in CRC. ESMO 2017 poster 138P (3) Data based on internal research data

Results

40 samples were characterized as defective MMR (dMMR) by IHC and MSI-H by the PCR-based method. reference The remaining 10 samples were characterized as proficient MMR (pMMR) by IHC and MSS by PCR. When the same set of 50 samples was analyzed by the Idylla MSI Assay, concordant results were obtained 40/40 MSI-H/dMMR samples and for 10/10 of the MSS/pMMR samples for an overall concordance of 100% (50/50). Additionally, the Idylla system was easy to use, required only 2 minutes of hands on time and produced results in as few as 150 minutes.

Conclusions

The Idylla platform offers a simple and fully automated solution for MSI status determination. The Idylla MSI Assay produces rapid results that are highly concordant with standard MSI/MMR testing methods.



Fluorescence Profile for a single Biomarker